The unintended twist of tax inversions

Steven Davidoff Solomon writes for The New York Times, April 24, 2015

Teva’s unsolicited $40 billion bid for the drug maker Mylan and Mylan’s own unsolicited offer for the rival Perrigo are sweet revenge for the United States taxpayer. The reason is their flight from the United States in tax inversions has made both more exposed to hostile takeovers.